| Business Summary | | VaxGen,
Inc.
was
formed
to
complete
the
development
of,
and
commercialize,
AIDSVAX,
a
preventive
HIV
(Human
Immunodeficiency
Virus)
vaccine.
The
original
AIDSVAX
technology
was
developed
by
Genentech
and
then
licensed
exclusively
to
the
Company.
VaxGen
is
currently
testing
AIDSVAX
in
humans
in
two
large-scale
Phase
III
clinical
trials.
The
Company's
vaccine
is
designed
to
prevent
infection
by
HIV,
rather
than
treat
established
infection.
The
Company
has
commenced
clinical
trials
in
North
America
and
Europe,
as
well
as
one
in
Thailand,
to
determine
the
efficacy
of
AIDSVAX. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VaxGen,
Inc.
is
a
development
stage
biotechnology
company
formed
to
develop
a
vaccine
intended
to
prevent
HIV
infection.
For
the
six
months
ended
6/30/01,
revenues
rose
from
$0
thousand
to
$421
thousand.
Net
loss
applicable
to
Common
rose
26%
to
$12.8
million.
Revenues
reflect
$346
thousand
in
revenue
from
a
project
funded
by
the
National
Institute
of
Allergy
and
Infectious
Diseases.
Higher
loss
reflects
higher
personnel
costs
and
professional
service
fees
and
$1
million
in
preferred
stock
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Donald Francis, M.D., 57 Pres,
CEO, Director | $275K | Carter Lee, 47 Sr.
VP, Fin. & Admin. | 185K | Phillip Berman, Ph.D., 50 Sr.
VP, R&D | 200K | John Curd, M.D., 54 Sr.
VP, Medical Affairs | 150K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|